Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) EPS (Weighted Average and Diluted): 2023-2024

Historic EPS (Weighted Average and Diluted) for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $112.62.

  • Inhibrx Biosciences' EPS (Weighted Average and Diluted) rose 19.72% to -$2.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.40, marking a year-over-year decrease of 110.40%. This contributed to the annual value of $112.62 for FY2024, which is 649.90% up from last year.
  • As of FY2024, Inhibrx Biosciences' EPS (Weighted Average and Diluted) stood at $112.62, which was up 649.90% from -$20.48 recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' EPS (Weighted Average and Diluted) registered a high of $112.62 during FY2024, and its lowest value of -$20.48 during FY2023.
  • In the last 2 years, Inhibrx Biosciences' EPS (Weighted Average and Diluted) had a median value of $46.07 in 2023 and averaged $46.07.
  • Data for Inhibrx Biosciences' EPS (Weighted Average and Diluted) shows a peak YoY soared of 649.90% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Inhibrx Biosciences' EPS (Weighted Average and Diluted) stood at -$20.48 in 2023, then spiked by 649.90% to $112.62 in 2024.